The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1423
ISSUE 1423
August 19, 2013
Issue 1423
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Canakinumab (Ilaris) for Systemic Juvenile Idiopathic Arthritis
August 19, 2013 (Issue: 1423)
The FDA has approved the interleukin-1 (IL-1) beta
inhibitor canakinumab (Ilaris – Novartis) for treatment of
systemic juvenile idiopathic arthritis (sJIA; formerly
called juvenile rheumatoid arthritis or Still’s disease) in
children ≥2...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.